welcome to oneFAPvoice- a positively charged Familial Adenomatous Polyposis community.
- join today!
Coxib-inhibition of Duodenal Polyp Growth in FAP
study id #: NCT00844727
condition: Duodenal Polyposis
Preliminary data indicate a protective effect on the development of duodenal polyps by coxib treatment. The hypothesis of the present study is that normal therapy doses of rofecoxib for 1 year would stop or reverse the development of premalignant adenomatous lesions in the duodenal mucosa of FAP patients.
start date: September 2003
estimated completion: April 2004
last updated: July 6, 2011
phase of development: Phase 2, Phase 3
size / enrollment: 38
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
- FAP patient with previous colectomy and confirmed polyposis
- NSAID hypersensitivity
expertly curated content related to this topic
Inherited Cancer Syndromes and the Thyroid: An UpdatePURPOSE OF REVIEW: Knowledge related to...
Non-Surgical Management of Attenuated and Deleterious (Classical) Familial Adenomatous Polyposis: A Long-term Survei...The primary objective of this chart revi...
Sulindac/Erlotinib Combo Tested in Patients with Familial Adenomatous PolyposisA lower duodenal polyp burden was seen a...
Familial Colon Cancer Syndromes: An Update of a Rapidly Evolving FieldColorectal cancer (CRC) is a major cause...
Exome Sequencing Identifies Biallelic MSH3 Germline Mutations as a Recessive Subtype of Colorectal Adenomatous Polyp...In ∼30% of families affected by colore...
Ostomy Tips And TricksThere is a pretty steep learning curve f...